Scientists map brain changes during Hour-Long DMT experience
NCT ID NCT07693257
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study investigates how a continuous intravenous infusion of DMT, a psychedelic substance, alters brain activity and perception over an extended period. Healthy volunteers with prior DMT experience will receive low and medium doses for one hour while undergoing fMRI scans. Researchers aim to identify brain patterns linked to the visual and emotional effects of DMT, providing insights into its neural mechanisms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N,N-dimethyltryptamine (DMT)
- What this could lead to
- If successful, this could reveal how DMT alters brain function during prolonged experiences, potentially informing future therapies for mood disorders.
- What could go wrong
- This is a small Phase 1 study in healthy volunteers, so results may not apply to broader populations. DMT can cause intense psychological effects, and the study does not test therapeutic benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altman Clinical and Translational Research Institute
La Jolla, California, 92037, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injectable drug safely tackle weight? an early trial seeks answers
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- First human trial launches for experimental drug BY002
- New drug BW-50218 put to first safety test in healthy chinese volunteers
- New COPD drug candidate AN01 begins first human safety tests
- New drug PRX019 takes first step: safety check in healthy people